stockrowPraxis Precision Medicines, Inc.
PRAX Healthcare Biotechnology
Praxis Precision Medicines, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8.6 million, up 249.5% from fiscal 2023.
- Revenue
- +1,349.1%
- EPS
- +13.3%
- Free cash flow
- −43.5%
Quarter to June 2026, against a year earlier
Follow PRAX
Alert me
Praxis Precision Medicines, Inc. (PRAX) Return on equity
Praxis Precision Medicines, Inc.'s return on equity over the twelve months to 30 June 2026 was −38.9%, up 7.0 percentage points from fiscal 2025 (−45.8%). Over the past ten years it has ranged from −169.1% (fiscal 2023) to 66.7% (fiscal 2019); the current reading is higher than 75% of that period. That is above the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −45.8% | 25.15 |
| FY2024 | −71.0% | 98.15 |
| FY2023 | −169.1% | (38.19) |
| FY2022 | −130.9% | (68.87) |
| FY2021 | −62.1% | 6.06 |
| FY2020 | −68.1% | (134.80) |
| FY2019 | 66.7% | 18.78 |
| FY2018 | 47.9% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| CYTK Cytokinetics, Incorporated compare | 184.7% |
| CORT Corcept Therapeutics Incorporated compare | 21.7% |
| KRYS Krystal Biotech, Inc. compare | 17.5% |
| PRAX Praxis Precision Medicines, Inc. | −38.9% |
| SYRE Spyre Therapeutics, Inc. compare | −41.2% |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | −64.9% |
| RYTM Rhythm Pharmaceuticals, Inc. compare | −167.5% |
| AXSM Axsome Therapeutics, Inc. compare | −175.6% |
| ABVX Abivax SA Sponsored ADR compare | −249.8% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)